We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eden Research Plc | EDEN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.10 | 2.60% | 3.95 | 08:12:22 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.90 | 3.90 | 3.95 | 3.95 | 3.85 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 18/11/2024 06:52 by supersonico Yes yes ....but I'm left with the question why does Humair Tariq have the job that involves Bio-Controls I Bio-Stimulants | Agriculture | Global Commercial | Sales & Marketing but Eden have not disclosed a Bio-stimulant product? Syngenta.. Humair's long term former employer has but Eden ..no Looks to me like Daniel Mulas García as Eden's Marketing | Product Manager | Biocontrol | PhD Agronomy United Kingdom ...is promoting Mevalone his former employer Sipcam's leading biopesticide product. He is not noted as selling Bio-stimulants. It occurs to me that Humair is likely doing the same and the Bio-simulant is an Eden / Syngenta product..yet to be announced. and Syngenta are imo likely large players in the development of the inthecoming Insecticide. |
Posted at 10/11/2024 08:22 by supersonico Stone Fruits;"There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years" .................... Investingisatrickyga It does imply that this approval will lead to other regulators viewing this and actioning the same. I'm looking at Almonds in California! Investingisatrickyga California produces 80% of the world's Almonds and is 100% of US production. Californian Almond crop production is expected to be 21% higher in 2024 over 2023. Almonds are California's 3rd most valuable crop. I fully expect Sipcam to get that label extension. .................... Biofungicide Label Extension in Spain 24 June 2024 This newly expanded label makes Araw one of the most versatile and reliable solutions to prevent fungal diseases in many crops under organic and conventional agriculture. Thanks to this new authorisation, obtained through Sipcam's local regulatory team, all relevant horticultural crops in Spain can now be protected with Araw representing an excellent opportunity in several crops of growing importance, such as avocado, mango, and almond, which has become the third largest tree crop in Spain after olives and grapes. Spain boasts the largest cultivated area of almond trees in the world and ranks third in terms of overall production. Eden anticipates that this growth of the addressable market for Araw will contribute to revenue in 2025 and beyond. Further details of this expansion will be provided in due course as commercialisation commences. Sean Smith, Chief Executive Officer of Eden Research, commented: "Today's announcement is an excellent demonstration of our strategy to pursue growth opportunities through both new product introductions and with existing products by targeting new crop types and new disease targets. We are delighted to build on the success of our longstanding relationship with Sipcam. They have done an outstanding job of making the Iberian region an important and strong revenue-generating territory for the Company. This label extension represents a significant additional growth opportunity for us. It not only includes numerous new crops and diseases, but it also includes a number of high-value crops that are particularly disease prone." |
Posted at 10/11/2024 08:14 by supersonico 15 December 2022Eden Research Plc ("Eden" or "Company") Distribution Agreement for Mevalone in France Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that it has signed an agreement ("Agreement") with Corteva France ("Corteva") which allows Corteva to market, distribute and sell Eden's fungicide product, Mevalone®, in France on an exclusive basis. Mevalone is Eden's flagship, sustainable, foliar biofungicide, which is used to treat Botrytis cinerea on grapes and various other crops, a fungal disease commonly found in crops exposed to humid conditions. Eden also recently received authorisation for the use of Mevalone on pome fruits, including apples and pears, in France to help treat post-harvest diseases that arise during storage, thereby significantly reducing food waste. .................... There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years. .................... France is widely recognised for its agricultural output, which is well-known for its high quality. France's vineyards are the country's biggest consumers of plant protection products, which include fungicides, insecticides, and herbicides. Although viticulture represents just 3% of France's agricultural land, the sector consumes 20% of the country's fungicides. It also represents 15% of French agricultural produce in value terms; an exciting landscape in which Eden's biopesticides will play an expanded role. The Agreement with Corteva will be implemented immediately with commercial progress expected over the course of the next year as Eden transitions from its current distribution arrangements. Sean Smith, CEO of Eden Research plc, commented: "Expanding our partnership with agriscience powerhouse Corteva reflects the further execution and acceleration of Eden's commercial strategy. Eden has a strong existing partnership with Corteva with our ongoing collaboration around the development of seed treatments, and this Agreement marks the expansion of our relationship with the focus of this Agreement being to increase Eden's commercial presence in the all-important French grape and pome fruits markets. "Corteva's vast presence in France will enable Eden to capitalise on the significant commercial opportunities that exist within this expansive market and has strong potential to increase Eden's product sales revenue. Coupled with our recently received EPA approval in the US, this Agreement highlights the global demand for sustainable biopesticides and the strides Eden is making to broaden its global footprint and accelerate commercial growth." Sylvain Bedel, Managing Director of Corteva France said: "We are pleased to be expanding our working relationship with Eden by supplying to farmers Eden's innovative bio-solutions in the French market. There is a strong demand for more sustainable growing practices in France and farmers are paying increasing attention to consumer demand for such practices. Eden's unique technology helps provide a much-needed solution." |
Posted at 09/11/2024 11:57 by supersonico Question,What's going on here? More studies? Are we seeing the preparation of 10X Corteva French model to coincide with Sipcam's enhanced Waynesboro US production capacity @18101 ? .. Smith , Sipcam "building their sustainable pesticide business in the US largely around Mevalone so we've all been eagerly anticipating this, they have absolutely hit the ground running" @3m.. Parallel French / USA label enhancement ? ... or nothing to see here? 12 May 2023 Regulatory approvals in California and Florida (Mevalone) These approvals follow regulatory authorisation from the United States Environmental Protection Agency (EPA) in September 2022 for all six petitions submitted by Eden (three active ingredients, two formulated products and Eden's Sustaine® polymer-free encapsulation technology; making up the building blocks of current and future products), . 9 January 2024 Brent Marek, CEO of Sipcam Agro USA, commented: "Mevalone is a highly effective, sustainable biofungicide. Mevalone provides the perfect natural solution for farmers in California adopting more sustainable growing practices. Sipcam Oxon SpA has enjoyed several years of success with Mevalone in key European countries such as Italy and Spain, and we look forward to working with the Eden team to bring this product to California, which is a significant addressable market in the US considering its production of high value crops such as grapes." 07 November 2024 Sales of Mevalone in the US were constrained in 2024 due to the timing of the approval in California (January 2024) which meant that it wasn't possible for Eden's distributor to undertake a full marketing campaign. In addition, the label of Mevalone, as approved in the US, has certain restrictions which may negatively impact sales in the short term. The Company is currently addressing these restrictions through studies, and the successful outcome of these should result in an increase in addressable market in the short to medium-term. |
Posted at 08/11/2024 10:40 by investingisatrickygame Alchemy,So Cavendish has a target of 20p and Eden say's in their opinion the shares are worth north of 20p. This is as of today. It doesn't take account of a full Ecovelex approval, an insecticide partner(s) and a Powdery Mildew approval in France for Esseva delivering up to 10* greater revenue than Mevalone treating Botrytis. It all adds up to a bargain share price of currently, 3.7p. So for those following the story, it offers a time to accumulate where desired and reassurance for those that are tapped out. To remind us, Ecovelex is a €33.8 million opportunity. As the Trading Update RNS stated yesterday, "However, the opportunity for the insecticide product could well surpass anything else we have done to date, and this is exciting for all of us." In other words, in my opinion, financial numbers stated in Eden presentations are likely understated. No cash needed! Question: What will Cavendish's price target be when these RNS's are delivered (expected soon according to Eden) and what will managements view of share price be at that stage? 3.7p is a ridiculous opportunity to invest in Eden with three triggers so close. |
Posted at 07/11/2024 22:12 by supersonico Second Ecovelex 2024 Approval announced ~6 weeks earlier than 2023.Full EU🧑&# .................... Eden Research and Corteva Agriscience Announce Ecovelex?2023 Approval in Italy Cremona, Italy and Abingdon, UK - December 18, 2023 - Corteva Agriscience and Eden Research are pleased to announce that Ecovelex? 2023 has been granted, according to Reg. EU/1107/2009, a temporary approval in Italy for use as a bird repellent seed treatment in corn for the 2024 growing season. Eden is an AIM listed company that develops and supplies sustainable solutions for crop protection, animal health and consumer products. ............. Ecovelex Approval in Italy 07 November 2024 Eden Research plc ("Eden") is pleased to announce that Ecovelex™ 2024 has been granted, according to Reg. EU/1107/2009, approval in Italy for use as a bird repellent seed treatment in corn for the 2025 growing season. Eden is a leader in sustainable biopesticide and biocontrol products and technologies. |
Posted at 23/10/2024 13:41 by supersonico Conspiracy theory?? hahaNot surprised as it was a conference call link from 2023..I expect they all have an expiry date. '''''''''''''''''''' Commentary extract came from this post; supersonico - 13 May 2023 - 07:09:20 - 14068 of 18967 Eden Research - EDEN Yes, Trials for seed treatment (coatings) which is due for commercialization for 2024 growing season and then I think he's referring to SustainE 'within' Pioneer seeds. Interesting Sam Eathington commentary @1hr29m in the Corteva Innovation Web cast in referring to EU approvals sounds very confident in Corteva's 'regulatory capacity to get things approved around the world is quite beneficial there'. Also Eden have Mike Carroll on hand as our trusty Corteva link man to provide network benefits. Also Smith's reference @6.17 to the 80 plus field trials for the insecticide treatment which could again be Corteva @Pioneer or Whale2. If it is Corteva then I'm even more inclined to think we'll see some sort of strategic partnership announcement. The Corteva French commentary regarding the 10x of addressable market that Smith refers to in the investor presentation event is making Corteva a very important partner and they may just want a bit of the ££benefit from the scale they bring to the party in what Sam Eathington calls 'unique value sharing collaborations'. “Our R&D program is also delivering innovation by moving faster on new opportunities such as biologicals to help farmers meet changing food production demands and the potential for double cropping systems that provide another cash crop option for farmers,â€ʏ Of course with Whale2 onboard as well Eden may have enough leverage to be considered 'external innovation' to them both. What anyone who is paying attention is certainly seeing is a step change in Eden's growth prospects and the PR noise that goes along with that. |
Posted at 29/9/2024 07:32 by supersonico Eden and Corteva seek to bring Ecovelex to marketGENEVA, Switzerland, 30 May, 2023 - Eden Research plc has applied for the authorization of Ecovelex™ in the EU, with application in the UK to follow, with Corteva Agriscience as its distribution partner. Eden is an AIM listed company that develops and supplies sustainable solutions for crop protection, animal health and consumer products. Eden has submitted the dossier and application to Austria, who will act as the interzonal rapporteur member state on behalf of the EU. Review and authorization can take between 18 and 24 months, with each EU member state then able to ratify the authorization or require additional information before granting local authorizations. .................... Full authorisation 18-24 months from 30 May, 2023. So 18 months - 24 months is November 24 ~May/June 2025. Costa says 'very soon' and his chart indicates 2025+ And Smith told us "they will be applying for EUA approval in Italy and possibly some additional territories. The question I have is ..Considering the habitual interzonal rapporteur delays Eden have encountered with non Ecovelex products and the precision 2021 prediction of a 2024 growing season experience that Ecovelex has had... Will the interzonal rapporteur treat Ecovelex in the favourable way they appear to have done as described above or will we experience the familiar pedestrian route with EUA's in additional territories as Smith indicated? A further indicator that Ecovelex may well continue to experience the #precision2021-24 treatment might be extrapolated from Abrey's recent statement where he specifically states an expected 'shorter time frame than three years to Peak'. He could not be confident of that timeline unless Ecovelex is anticipated to get the #precision2021-24 treatment... could he?. Abrey Sept 24- Ecovelex .."so overall we see this as an opportunity that's actually bigger than Mevelone and Cedroz put together so around 34 million euros in the EU UK Alone we're looking at about 3.6 million euros a peak for this particular use we expect that to be a shorter time frame than three years to Peak because of those same drivers and we're very far through the process of seeking full approval for the product we've talked about the emergency use authorizations one of which we successfully received last year which led to a material sale of product to Cortiva so this is a big one for us we're very excited about it we've made a good amount of progress and that's it's been a really good project" AWGATWT. |
Posted at 25/9/2024 15:40 by investingisatrickygame If you refer to Eden's presentations and add up the aggregate sales per annum over each product at peak sales within 3 years from launch, they predict circa £130 million per annum. So if they were all at 3 years, purely for illustration, and had 10 years in front of them, possibly £1.3 billion or more in salesA regulatory approval can last 10-15 years as I understand it and of course, can be renewed. Eden has a large pipeline of opportunities, they say. The Chairman stated in the half yearly report, that 'the potential for Eden is huge' The CEO said 'We anticipate the remainder of the year will provide plenty of reasons for excitement' The CFO in the Q and A re-iterated that it takes around $300 million and 10-12 years to develop a successful pesticide, yet Eden has spent £20 million to get us to where we are today (4 products if we include our insecticide), thus offering significant additional profit opportunity as there is less cost to recover. Does any of this sound like a 4p per share company? I don't think so. Does any of this sound like a 20p per share company as per the Cavendish forecast? I don't think so. 50p a share values Eden at £267 million and Eden's gross margins as highlighted by the Company themselves, provide massive headroom to run the Company and return more than 50p a share. The regulatory approved footprint alone, in my opinion is already worth a lot of money, but 'the market' doesn't seem to have caught on with where Eden are OR Eden in its communications has not reached a sufficiently big wide enough audience in order to convince more people to realise the value already in Eden. |
Posted at 04/9/2024 17:33 by investingisatrickygame Value lies in regulatory approvals. Secondary and much increased value lies in sales. Then, profit.Eden has USP's. Eden has regulatory footprint. Eden has enthusiastic global ag partners. Eden has pending approvals and submissions on products greater than those already approved. Eden has a bright future!!!! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
